Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GBIO Generation Bio	$6.29 -5.6%	$4.15	$3.00 ▼ $29.40	$42.37M	2.67	854,522 shs	188,256 shs
JATT JATT Acquisition	$1.66 -3.5%	$1.36	$7.80 ▼ $12.38	$28.64M	N/A	41,322 shs	471,199 shs
OKUR OnKure Therapeutics	$2.53 -5.2%	$2.41	$1.70 ▼ $20.00	$34.18M	0.4	124,222 shs	190,952 shs
PLRZ Polyrizon	$1.10 -1.8%	$0.97	$0.55 ▼ $1,200.00	$6.59M	N/A	10.35 million shs	627,609 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GBIO Generation Bio	-5.56%	+53.41%	+11.33%	+64.96%	-73.00%
JATT JATT Acquisition	+8.18%	+16.22%	+32.31%	+54.95%	-47.72%
OKUR OnKure Therapeutics	-5.24%	+24.02%	+1.61%	+26.50%	+252,999,900.00%
PLRZ Polyrizon	-1.79%	0.00%	+4.76%	-33.33%	+109,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GBIO Generation Bio	3.2886 of 5 stars	3.3	3.0	0.0	0.0	2.1	3.3	1.3
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	3.4352 of 5 stars	3.7	0.0	0.0	0.0	3.3	2.5	1.3
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GBIO Generation Bio	2.67	Moderate Buy	$37.33	493.53% Upside
JATT JATT Acquisition	0.00	N/A	N/A	N/A
OKUR OnKure Therapeutics	3.33	Buy	$32.33	1,178.00% Upside
PLRZ Polyrizon	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PLRZ, GBIO, JATT, and OKUR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	GBIO Generation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$7.00 ➝ $7.00
8/13/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
7/18/2025	GBIO Generation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00 ➝ $70.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GBIO Generation Bio	$19.89M	2.13	N/A	N/A	$8.03 per share	0.78
JATT JATT Acquisition	N/A	N/A	$0.06 per share	27.08	($0.53) per share	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	$5.79 per share	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	$315.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GBIO Generation Bio	-$131.67M	-$10.82	N/A	N/A	-341.12%	-91.07%	-33.65%	N/A
JATT JATT Acquisition	$6.85M	N/A	∞	N/A	N/A	-49.58%	2.84%	N/A
OKUR OnKure Therapeutics	-$52.67M	-$4.80	N/A	N/A	N/A	-60.52%	-55.43%	N/A
PLRZ Polyrizon	-$1.54M	N/A	∞	N/A	N/A	N/A	N/A	N/A

Latest PLRZ, GBIO, JATT, and OKUR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	GBIO Generation Bio	-$2.80	-$3.12	-$0.32	-$3.12	$2.51 million	$0.77 million
8/12/2025	Q2 2025	OKUR OnKure Therapeutics	-$1.23	-$1.14	+$0.09	-$1.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
JATT JATT Acquisition	N/A	N/A	N/A	N/A	N/A
OKUR OnKure Therapeutics	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GBIO Generation Bio	N/A	7.51	8.43
JATT JATT Acquisition	N/A	0.15	0.15
OKUR OnKure Therapeutics	N/A	11.13	11.17
PLRZ Polyrizon	N/A	10.16	10.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GBIO Generation Bio	95.22%
JATT JATT Acquisition	47.97%
OKUR OnKure Therapeutics	90.98%
PLRZ Polyrizon	N/A

Insider Ownership

Company	Insider Ownership
GBIO Generation Bio	21.80%
JATT JATT Acquisition	20.00%
OKUR OnKure Therapeutics	2.30%
PLRZ Polyrizon	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GBIO Generation Bio	150	6.74 million	5.27 million	Optionable
JATT JATT Acquisition	3	17.25 million	13.80 million	Not Optionable
OKUR OnKure Therapeutics	N/A	13.51 million	13.20 million	N/A
PLRZ Polyrizon	N/A	5.99 million	N/A	N/A

PLRZ, GBIO, JATT, and OKUR Headlines

Recent News About These Companies

Polyrizon Regains Nasdaq Compliance

August 14 at 12:26 PM | msn.com

Polyrizon Ltd. Regains Compliance with Nasdaq Listing Requirements

August 14 at 8:24 AM | quiverquant.comQ

Polyrizon Regains Compliance with Nasdaq Listing Requirements

August 14 at 8:14 AM | globenewswire.com

Polyrizon Ltd. Announces Special General Meeting for September 2025

July 31, 2025 | tipranks.com

Polyrizon stock soars after promising nasal allergy blocker test results

July 23, 2025 | in.investing.com

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

July 22, 2025 | globenewswire.com

Polyrizon Ltd.: Polyrizon Retains Nasdaq Listing Following Hearings Panel

July 15, 2025 | finanznachrichten.de

Polyrizon retains Nasdaq listing following hearings panel

July 15, 2025 | msn.com

Polyrizon Retains Nasdaq Listing Following Hearings Panel

July 15, 2025 | globenewswire.com

Polyrizon’s nasal drug delivery system shows promising results

June 14, 2025 | uk.investing.com

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its ...

June 12, 2025 | bakersfield.comB

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

June 12, 2025 | globenewswire.com

Polyrizon Ltd. Receives Nasdaq Notification of Potential Delisting Due to Shareholder Dilution Concerns

May 23, 2025 | quiverquant.comQ

Polyrizon Announces Receipt of Nasdaq Delisting Notice

May 23, 2025 | globenewswire.com

Polyrizon Ltd. Announces Reverse Share Split Effective May 27, 2025

May 22, 2025 | tipranks.com

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

May 21, 2025 | globenewswire.com

Polyrizon Ltd. Announces Increase in Outstanding Shares Following Warrant Exercises

May 14, 2025 | tipranks.com

Polyrizon Ltd.: Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

May 13, 2025 | finanznachrichten.de

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

May 13, 2025 | globenewswire.com

Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest

May 5, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLRZ, GBIO, JATT, and OKUR Company Descriptions

Generation Bio NASDAQ:GBIO

$6.29 -0.37 (-5.56%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$6.58 +0.29 (+4.53%)

As of 08/15/2025 07:42 PM Eastern

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

JATT Acquisition NYSE:JATT

$1.66 -0.06 (-3.49%)

As of 08/15/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

OnKure Therapeutics NASDAQ:OKUR

$2.53 -0.14 (-5.24%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.44 -0.09 (-3.75%)

As of 08/15/2025 07:59 PM Eastern

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

Polyrizon NASDAQ:PLRZ

$1.10 -0.02 (-1.79%)

As of 08/15/2025 04:00 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time